WuXi Biologics (Cayman) Inc. (WXIBF) Stock Price & Analysis
WuXi Biologics (Cayman) Inc. (WXIBF) — price $6.77 (0.00%), as of the Oct 2, 2026 trading session; market cap $27.9B.
Educational signal · not a buy or sell recommendation · How to read this
WuXi Biologics (Cayman) Inc. · WXIBF · Healthcare · Biotechnology
WuXi Biologics (Cayman) Inc. provides extensive global services, spanning the entire biopharmaceutical process from drug discovery to advanced development and manufacturing, catering to clients in China, North America, Europe, and other international…
Price as of Oct 2, 2026
Key Statistics
No publishable V2 score is available for this stock yet.
Price & valuation
| Measure | Value | As of |
|---|---|---|
| Latest provided price | $6.77 | |
| Change on the day | 0.00% | |
| 52-week range | $3.90–$6.77 | |
| Market capitalisation | $27.9B | |
| Price / earnings (trailing) | 38.47 | |
| Shares traded on the day | 4.0K | |
| Beta (volatility vs the S&P 500) | 0.6 |
Price & events
Point at or tab to any week for its close.
Other perspectives
Council score for WuXi Biologics (Cayman) (WXIBF): perspectives
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
9-Factor Breakdown
Legends Council
4 lenses, 0 current
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Read on: Sep 9, 2026 · older than the 27 hours refresh window; not a current reading
Munger's Mindset
Balance Sheet & Valuation · historical
Read on: Sep 9, 2026 · older than the 27 hours refresh window; not a current reading
How to read these bars and different assessments
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.
On Sep 9, 2026, the Munger lens read the price at that time as fairly valued against its own estimate of value.
Readings on this page are from Oct 5, 2026, except a card that shows its own read date.
Watch the WXIBF film — every key number, told as a short cinematic story
~2 min · open the film
What is WuXi Biologics (Cayman) (WXIBF), and what does it report?
Short answer · as of
WuXi Biologics (Cayman) Inc. provides extensive global services, spanning the entire biopharmaceutical process from drug discovery to advanced development and manufacturing, catering to clients in China, North America, Europe, and other international… WuXi Biologics (Cayman) Inc. (WXIBF) is classified as Healthcare / Biotechnology. Headquarters: No. 108, Meiliang Road, Wuxi, JS, 214092, CN. It employs 13,252 people and is led by Zhisheng Chen. In Q2 FY2026 it reported revenue of $1.73B and net income of $359M. The market values it at $27.9B.
What do the latest results show for WuXi Biologics (Cayman) (WXIBF)?
Short answer · as of
The most recent reported quarter, Q2 FY2026, carried revenue of $1.73B. Against analyst estimates the company has EPS beat 4 of 8 reports.
Quarterly income statement — 4 quarters
| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Q2 FY2026 | $1.73B | $359M | $0.09 (diluted) |
| Q4 FY2025 | $1.74B | $377M | $0.09 (diluted) |
| Q2 FY2025 | $1.48B | $349M | $0.08 (diluted) |
| Q4 FY2024 | $1.51B | $277M | $0.07 (diluted) |
What are the financial strengths and risks for WuXi Biologics (Cayman) (WXIBF)?
Short answer
The distress and quality screens read Altman Z 12.09 · Piotroski F 9. Trailing ratios: ROE 10.5% · ROA 7.7% · current ratio 3.04 · earnings yield 2.6% · free-cash-flow yield 2.3%.
What has been published about WuXi Biologics (Cayman) (WXIBF)?
Common Questions About WXIBF (Healthcare)
These answers are editorial: 1 of these 8 answers is drawn from the WXIBF research dossier (written Mar 17, 2026 by gemini-2.0-flash); the other 7 are question templates that restate figures shown above. Figures in this section are not part of the source register.
Is WXIBF a good stock to buy?
Stock Expert AI does not rate WXIBF buy, sell or hold. WuXi Biologics (Cayman) Inc. has no MoonshotScore yet; read the financial checkup, analyst consensus and risks directly. Whether it fits is your call: check what it sells, whether it earns and what the price assumes. This is educational content, not investment advice.
What is the WXIBF stock price today?
The last price recorded on this page for WuXi Biologics (Cayman) Inc. (WXIBF) is $6.77, as of the Oct 2, 2026 trading session (source: Financial Modeling Prep (FMP) · quote). It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.
What does WuXi Biologics (Cayman) Inc. do?
WuXi Biologics (Cayman) Inc. is a leading global contract development and manufacturing organization (CDMO) that provides end-to-end solutions for biologics.
What are the key factors to evaluate for WXIBF?
Evaluate WXIBF on fundamentals, analyst consensus, and risk factors. P/E: 38.47x. Expansion into New Therapeutic Areas: WuXi Biologics can drive growth by expanding its service offerings into emerging therapeutic areas such as cell and gene therapy. Not financial advice.
How frequently does WXIBF data refresh on this page?
WXIBF's price is the last quote we recorded, from the Oct 2, 2026 trading session. Pages are served from a cache, so the copy you are reading can lag that quote. The quote is a provider snapshot, not an exchange feed. Fundamentals follow quarterly filings. V2 is recalculated from the most recent completed US trading session; the score's own date shows its last successful run.
What has driven WXIBF's recent stock price performance?
WuXi Biologics (Cayman) Inc. (WXIBF) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Comprehensive service offerings. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider WXIBF overvalued or undervalued right now?
WuXi Biologics (Cayman) Inc. (WXIBF) trades at 38.47x earnings. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
How do I research WXIBF before investing?
Before investing in WuXi Biologics (Cayman) Inc. (WXIBF), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated Mar 17, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.
Sources — records for every figure on this page (19 figures)
The 19 rows below are exactly the facts the evidence-backed sections of this page printed — the 10-second verdict, the MoonshotScore, price and market value, the five questions with their receipts, and the records behind this page. Known dates and sources are recorded on their own rows; an em dash or UNRECORDED tier preserves a stored observation without inventing either. The quarterly income statement is provider-standardized (FMP) under one row, and scale definitions — a 0-100 rating, the band ladder, the Piotroski 0–9 range — are fixed rather than measured. No number in those sections was generated by a model. The register does not cover quoted third-party headlines, the dated council readings, or the Frequently Asked Questions; each of those says where it came from where it stands.
"As of" is the date the value is true for where the source carries one — a quarter end, a filing date, a price close, the day the score was computed. A cached observation with no source date remains undated; the page publication date is not used as a substitute.
FMP — 16 facts from Financial Modeling Prep endpoint families
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
px.last | Latest provided price | $6.77 | FMP | Financial Modeling Prep (FMP) · quote — Dated to the US trading session the price belongs to, derived from the quote record's timestamp (weekend and pre-open reads roll back to the previous weekday; exchange holidays are not modelled). The record does not establish an exchange execution time. Retrieved 2026-10-04T21:14:26.410Z. | |
px.change | Change on the day | 0.00% | FMP | Financial Modeling Prep (FMP) · quote | |
px.mcap | Market capitalization | $27.9B | FMP | Financial Modeling Prep (FMP) quote — Provider market cap uses the share class it prices; a company with more than one class may show a larger total elsewhere. Market cap record date: 2026-10-04. Source capture time was not supplied. No share-count basis is inferred; this page preserves the reported amount instead of recalculating it from shares. | |
id.business_summary | Business description (FMP excerpt) | WuXi Biologics (Cayman) Inc. provides extensive global services, spanning the entire biopharmaceutical process from drug discovery to advanced development and manufacturing, catering to clients in China, North America, Europe, and other international… | FMP | Financial Modeling Prep (FMP) company profile — Deterministic excerpt derived from id.description; source and date describe the input fact, not a new provider observation | |
px.change_abs | Change on the day, in dollars | $0.00 | FMP | Financial Modeling Prep (FMP) · quote | |
px.range52 | 52-week range | $3.90–$6.77 | FMP | Financial Modeling Prep (FMP) quote | |
px.pe | Price / earnings (trailing) | 38.47 | FMP | Financial Modeling Prep (FMP) · quote | |
px.volume | Shares traded on the day | 4.0K | FMP | Financial Modeling Prep (FMP) · quote | |
px.beta | Beta | 0.6 | FMP | Financial Modeling Prep (FMP) company profile | |
id.sector | Sector / industry (provider taxonomy) | Healthcare / Biotechnology | FMP | Financial Modeling Prep (FMP) company profile | |
id.hq | Headquarters | No. 108, Meiliang Road, Wuxi, JS, 214092, CN | FMP | Financial Modeling Prep (FMP) company profile | |
id.employees | Employees | 13,252 | FMP | Financial Modeling Prep (FMP) company profile | |
id.ceo | Chief executive | Zhisheng Chen | FMP | Financial Modeling Prep (FMP) key executives (proxy-derived) — Titles and pay come from the company's proxy statement as our provider parsed it. | |
fin.q_revenue | Revenue, Q2 FY2026 | $1.73B | FMP | Financial Modeling Prep (FMP) · income statement (quarterly) | |
fin.q_income | Net income, Q2 FY2026 | $359M | FMP | Financial Modeling Prep (FMP) · income statement (quarterly) | |
fin.q_table | Quarterly income statement | 4 quarters through Q2 FY2026 | FMP | Financial Modeling Prep (FMP) · income statement (quarterly), as filed |
UNRECORDED — 3 facts from stored observations whose source was not recorded
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
earn.history | Reported versus estimated, recent quarters | EPS beat 4 of 8 | UNRECORDED | Stored earnings-history observation — Captured 2026-09-21 · Expired observation | |
fin.scores | Distress and quality screens | Altman Z 12.09 · Piotroski F 9 | UNRECORDED | Stored financial-scores observation — Captured 2026-10-04 | |
fin.ratios | Return and yield ratios (trailing twelve months) | ROE 10.5% · ROA 7.7% · current ratio 3.04 · earnings yield 2.6% · free-cash-flow yield 2.3% | — | UNRECORDED | Stored key metrics — Date unknown |
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com
Data provided for informational purposes only.